Risk Stratification and Patient Selection

Beyond TP53 mutations, several molecular and clinical characteristics influence treatment intensification decisions. Dr. Rodriguez emphasizes that patient factors including age, comorbidities, and chemotherapy tolerance capacity must be considered alongside molecular features.

L858R mutations represent another poor prognostic indicator where combination therapy benefits have been demonstrated across both FLAURA2 and MARIPOSA studies. Brain metastases constitute a critical high-risk feature where both combination regimens show superior outcomes compared to monotherapy approaches.

The challenge remains identifying patients suitable for monotherapy, as several patients achieve years of disease control with osimertinib alone. However, lacking definitive biomarkers for low-risk patients, most practitioners default to combination approaches given overall survival advantages.

Dr. Olazagasti describes an elderly patient who refused combination therapy but achieved excellent outcomes with monotherapy despite high-risk features. She emphasizes the option of adding chemotherapy later if initial responses prove inadequate, though acknowledging limitations of this approach based on progression patterns and resistance mechanisms.

The panelists note that although COMPEL data suggests benefits for adding chemotherapy at progression, they lack sufficient information about patient characteristics, progression sites, and molecular evolution to confidently recommend reserving intensification for progression. Historical experience shows that some patients "crash and burn" with rapid progression despite initial EGFR mutation enthusiasm.

Age alone should not exclude patients from combination therapy, particularly in regions where chronologic age may not reflect functional status. The goal involves maximizing both longevity and quality of life, requiring aggressive upfront approaches rather than sequential treatment strategies.